(Total Views: 1005)
Posted On: 06/07/2019 7:34:18 AM
Post# of 30066
A Blood Test for Cancer...
Right now there is Colonoscopy and
EXAS - poop in a box ....
That stock went from .25 in 2007 to over $100 today.
TBIA platform - a blood test for the detection of Cancers
TM-B1 and TM-B2 are CE marked in the EU.
TM-B1 - will support current cancer diagnostic protocols in their weak points (like dense breast tissue and young woman) and give a simple and low-cost solution for early detection.
TM-B2 - allow health care providers to distinguish between benign and malignant breast tumors.
They already got the go ahead to Market and sell within Israel with the Israeli Ministry Of Health.
They signed exclusive distribution and sales agreement with them.
Todos has already met with the FDA
FDA will accept Ex-US DATA
FDA also wants them to them to test in US.
They are working on finding the right US Lab partner.
Will be doing CLIA in parallel
That is important becase that allows them to sell the test based on accepted EX-US data.
Will launch initial pilot studies in 2 European countries Q3 2019
Austria & Romania.
TM-C1
Lung Cancer - new data http://todosmedical.com/lung-cancer-test/
Ovarian Cancer - new discussion
With IPO and NASDAQ uplist in the next 3-5 weeks planned
Amarantus owns 49.9%
With Todos moving towards a Nasdaq listing, much of our attention has focused on our subsidiary Elto Pharma’s transaction with Coeptis Pharmaceuticals,
http://wsw.com/webcast/ldmicro16/register.asp...index.aspx
Coeptis
Once the deal is completed Amarantus will own roughly 50% of Coeptis.
Coeptis recently completed a transaction to gain rights to an FDA-approved drug it expects to launch later in 2019, thereby potentially providing cash flow to support eltoprazine's further development, as well as possibly mitigating Amarantus-owned equity dilution in Coeptis down the road.
https://www.amarantus.com/news/press-releases...19-roadmap
We anticipate launching Consensi™ in the second half of 2019 and expect to have it widely available to the millions of Americans who can benefit from this combination treatment.” David Mehalick, CEO of Coeptis
http://coeptispharma.com/kitov-signs-marketin...ceuticals/
Cutanogen -
Looking at very strategic transactions
Actively designing Phase 3 trial.
MANF - Spinoff as a standalone
https://investorshangout.com/post/view?id=545...z5qA1IaN8S
As noted in our recent quarterly filing, we’ve further amended the Tender Exchange agreements with our secured and unsecured debt holders to provide sufficient time to complete a Regulation A+ offering (Reg A).
https://investorshangout.com/post/view?id=545...z5qA1fbbaY
Aloha
Right now there is Colonoscopy and
EXAS - poop in a box ....
That stock went from .25 in 2007 to over $100 today.
TBIA platform - a blood test for the detection of Cancers
TM-B1 and TM-B2 are CE marked in the EU.
TM-B1 - will support current cancer diagnostic protocols in their weak points (like dense breast tissue and young woman) and give a simple and low-cost solution for early detection.
TM-B2 - allow health care providers to distinguish between benign and malignant breast tumors.
They already got the go ahead to Market and sell within Israel with the Israeli Ministry Of Health.
They signed exclusive distribution and sales agreement with them.
Todos has already met with the FDA
FDA will accept Ex-US DATA
FDA also wants them to them to test in US.
They are working on finding the right US Lab partner.
Will be doing CLIA in parallel
That is important becase that allows them to sell the test based on accepted EX-US data.
Will launch initial pilot studies in 2 European countries Q3 2019
Austria & Romania.
TM-C1
Lung Cancer - new data http://todosmedical.com/lung-cancer-test/
Ovarian Cancer - new discussion
With IPO and NASDAQ uplist in the next 3-5 weeks planned
Amarantus owns 49.9%
With Todos moving towards a Nasdaq listing, much of our attention has focused on our subsidiary Elto Pharma’s transaction with Coeptis Pharmaceuticals,
http://wsw.com/webcast/ldmicro16/register.asp...index.aspx
Coeptis
Once the deal is completed Amarantus will own roughly 50% of Coeptis.
Coeptis recently completed a transaction to gain rights to an FDA-approved drug it expects to launch later in 2019, thereby potentially providing cash flow to support eltoprazine's further development, as well as possibly mitigating Amarantus-owned equity dilution in Coeptis down the road.
https://www.amarantus.com/news/press-releases...19-roadmap
We anticipate launching Consensi™ in the second half of 2019 and expect to have it widely available to the millions of Americans who can benefit from this combination treatment.” David Mehalick, CEO of Coeptis
http://coeptispharma.com/kitov-signs-marketin...ceuticals/
Cutanogen -
Looking at very strategic transactions
Actively designing Phase 3 trial.
MANF - Spinoff as a standalone
https://investorshangout.com/post/view?id=545...z5qA1IaN8S
As noted in our recent quarterly filing, we’ve further amended the Tender Exchange agreements with our secured and unsecured debt holders to provide sufficient time to complete a Regulation A+ offering (Reg A).
https://investorshangout.com/post/view?id=545...z5qA1fbbaY
Aloha
(4)
(0)
